Jeroen Hoogland1, Judith A Boel1,2, Rob M A de Bie1, Ben A Schmand2,3, Ronald B Geskus4,5,6, John C Dalrymple-Alford7, Connie Marras8, Charles H Adler9, Daniel Weintraub10, Carmen Junque11, Kenn F Pedersen12, Brit Mollenhauer13, Jennifer G Goldman14, Alexander I Tröster15, David J Burn16, Irene Litvan17, Gert J Geurtsen3. 1. Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. 2. Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands. 3. Department of Medical Psychology, Academic Medical Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. 4. Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. 5. Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom. 6. Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme, Ho Chi Minh City, Vietnam. 7. New Zealand Brain Research Institute, Brain Research New Zealand - Rangahau Roro Aotearoa, Christchurch, New Zealand. 8. Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, University of Toronto, Ontario, Canada. 9. Arizona Parkinson's Disease Consortium, Mayo Clinic Arizona, Scottsdale, Arizona, USA, and Banner Sun Health Research Institute, Sun City, Arizona, USA. 10. Departments of Psychiatry and Neurology, University of Pennsylvania School of Medicine, and Parkinson's Disease and Mental Illness Research, Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA. 11. Department of Medicine, Faculty of Medicine, IDIBAPS, University of Barcelona, Barcelona, Spain. 12. The Norwegian Centre for Movement Disorders, Department of Neurology, and Memory Clinic, Stavanger University Hospital, Stavanger, Norway. 13. Department of Neurosurgery and Institute of Neuropathology, Paracelsus-Elena-Klinik, Kassel, Germany, and University Medical Center Goettingen, Goettingen, Germany. 14. Department of Neurological Sciences, Section of Parkinson Disease and Movement Disorders, Rush University Medical Center, Chicago, Illinois, USA. 15. Department of Clinical Neuropsychology and Center for Neuromodulation, Barrow Neurological Institute, Phoenix, Arizona, USA. 16. Institute of Neuroscience, Newcastle University, Upon Tyne, Newcastle, UK. 17. Department of Neurosciences University of California San Diego, Parkinson and Other Movement Disorder Center, San Diego, California, USA.
Abstract
BACKGROUND: The International Parkinson and Movement Disorders Society criteria for mild cognitive impairment in PD need validation. The objectives of this present study were to evaluate prognostic validity of level I (abbreviated) International Parkinson and Movement Disorders Society mild cognitive impairment in PD criteria for development of PD dementia and compared them with level II (comprehensive) criteria. METHODS: We analyzed data from 8 international studies (1045 patients) from our consortium that included baseline data on demographics, motor signs, depression, detailed neuropsychological testing, and longitudinal follow-up for conversion to Parkinson's disease dementia. Survival analysis evaluated their contribution to the hazard of Parkinson's disease dementia. RESULTS: Level I mild cognitive impairment in PD, increasing age, male sex, and severity of PD motor signs independently increased the hazard of Parkinson's disease dementia. Level I and level II mild cognitive impairment in PD classification had similar discriminative ability with respect to the time to Parkinson's disease dementia. CONCLUSIONS: Level I mild cognitive impairment in PD classification independently contributes to the hazard of Parkinson's disease dementia. This finding supports the prognostic validity of the abbreviated mild cognitive impairment in PD criteria.
BACKGROUND: The International Parkinson and Movement Disorders Society criteria for mild cognitive impairment in PD need validation. The objectives of this present study were to evaluate prognostic validity of level I (abbreviated) International Parkinson and Movement Disorders Society mild cognitive impairment in PD criteria for development of PD dementia and compared them with level II (comprehensive) criteria. METHODS: We analyzed data from 8 international studies (1045 patients) from our consortium that included baseline data on demographics, motor signs, depression, detailed neuropsychological testing, and longitudinal follow-up for conversion to Parkinson's disease dementia. Survival analysis evaluated their contribution to the hazard of Parkinson's disease dementia. RESULTS: Level I mild cognitive impairment in PD, increasing age, male sex, and severity of PD motor signs independently increased the hazard of Parkinson's disease dementia. Level I and level II mild cognitive impairment in PD classification had similar discriminative ability with respect to the time to Parkinson's disease dementia. CONCLUSIONS: Level I mild cognitive impairment in PD classification independently contributes to the hazard of Parkinson's disease dementia. This finding supports the prognostic validity of the abbreviated mild cognitive impairment in PD criteria.
Authors: Dag Aarsland; Lucia Batzu; Glenda M Halliday; Gert J Geurtsen; Clive Ballard; K Ray Chaudhuri; Daniel Weintraub Journal: Nat Rev Dis Primers Date: 2021-07-01 Impact factor: 52.329
Authors: Zhi Zhou; Martijn L T M Müller; Prabesh Kanel; Jason Chua; Vikas Kotagal; Daniel I Kaufer; Roger L Albin; Kirk A Frey; Nicolaas I Bohnen Journal: Neurology Date: 2019-11-15 Impact factor: 9.910
Authors: Elizabeth R Wallace; Suzanne C Segerstrom; Craig G van Horne; Frederick A Schmitt; Lisa M Koehl Journal: Neuropsychol Rev Date: 2021-04-16 Impact factor: 7.444
Authors: Kyla-Louise Horne; Michael R MacAskill; Daniel J Myall; Leslie Livingston; Sophie Grenfell; Maddie J Pascoe; Bob Young; Reza Shoorangiz; Tracy R Melzer; Toni L Pitcher; Tim J Anderson; John C Dalrymple-Alford Journal: Mov Disord Clin Pract Date: 2021-02-18
Authors: Hojoong M Kim; Carter Nazor; Cyrus P Zabetian; Joseph F Quinn; Kathryn A Chung; Amie L Hiller; Shu-Ching Hu; James B Leverenz; Thomas J Montine; Karen L Edwards; Brenna Cholerton Journal: Clin Park Relat Disord Date: 2019-10-20